IEET > Vision > Contributors > David Kekich > HealthLongevity > Technoprogressivism > Innovation
2015 Was a Great Year for Longevity
David Kekich   Dec 31, 2015  

Dear Future Centenarian,   
I usually hate seeing another year go by, especially with advancing age. 2015 was different though. So many longevity advancements can’t help but stir your optimism.

An approved clinical trial for longevity? Whoever thought it would happen this soon?
On June 24th, researchers met with regulators from the US Food and Drug Administration (FDA) to make the case for a clinical trial designed to show the validity of the approach.
Nir Barzilai of the Albert Einstein College of Medicine in New York and other researchers plan a clinical trial called Targeting Aging with Metformin, or TAME. They will give the drug metformin to thousands of people who already have one or two of three conditions — cancer, heart disease or cognitive impairment — or are at risk of them.

 Researchers convinced FDA officials that if the trial succeeds, they will have proved that a drug can delay aging. That would set a precedent that aging is a disorder that can be treated with medicines, and perhaps spur progress and funding for aging research.
The diabetes medication metformin will be tested as a possible “anti-aging” drug in human trials in 2016 as researchers try to determine if it can actually boost longevity. The U.S. FDA has given a green light for the trial.
Even more encouraging is… gene therapy entered its first human longevity study last September. Rather than wait decades to see if lifespans can be extended, this trial is designed to reverse observable effects of aging within a year.
I wrote of this BioViva, USA study in previous issues. The company plans to offer offshore treatments next year via medical tourism shortly after funding is secured.
Do you remember the parabiosis medical technology that hit the news? Old mice that had their circulatory systems connected to young mice circulatory systems became physiologically younger. Now Life Extension Foundation plans a $10M study that will inject selected pro-youthful growth factors into elderly patients separated from blood donated by young humans. They hope to erase 1-2 decades from aged patients.
Life Extension is seeding the funding with a $1M donation.
In addition to Google’s Calico project, Google Ventures committed $425M to longevity research.
Then the gene editing technology, CRISPR, made amazing headway, especially with the trail blazing work by Dr. George Church of Harvard Univ. CRISPR’s implications for aging are enormous.
There’s more. A step here and a leap there in labs all around the world. I may just lift a New Year’s glass of champagne and toast all the dedicated researchers, donors ranking from individuals to small and large institutions like the Foster Foundation, entrepreneurs and investors who are making all this happen for you and me.
More Life… and Happy New Year

David Kekich 

David Kekich founded in 199 "Maximum Life Foundation", dedicated to reversing human aging and aging related diseases. He raises funds for life-extending research, and serves as a Board Member of the American Aging Association, Life Extension Buyers’ Club and Alcor Life Extension Foundation Patient Care Trust Fund. He currently serves as CEO of SciCog Systems and Age Reversal, Inc.


Mr Kekich, I get your email newsletters all the time, and really appreciate them, sometimes reposting them on Facebook.

I am very excited about one particular emerging technology: gene therapy.  A company called BioViva will shortly introduce the first commercially available gene therapy longevity treatment in their Mexican and Columbian clinics.  It is particularly pertinent for me at age 55, since it ought to extend my healthy lifespan for decades, long enough to make it to the Singularity (with luck).

“BioViva is a new company offering experimental medical services outside US borders.  Their team includes

a lab that provides genetically modified viruses with a gene payload, made to order.  (This has now become a reliable and predictable technology.)
A doctor who has experience with experimental gene therapy, and who had the courage to experiment on himself five years ago, with good outcome thus far.
Sites in Colombia and Mexico where doctors will administer therapies for which there is not yet FDA approval.
Most important, a Scientific Advisory Board that includes two of the most prominent, senior biochemists who developed the science of telomerase in the 1990s and before.  They are Bill Andrews and Michael Fossel.
What they offer is gene therapy with hTERT and a proprietary myostatin inhibitor “in the same family with GDF-11,” according to CEO Elizabeth Parrish.”

Again Mr Kekich, thank you very much for all the work and time you put in in the name of extending people’s lifespans.  You may be responsible for saving the lives of a tremendous number of people with the knowledge you distribute.

Here is an example of what I am referring to from an email I got on Thursday:

“The guru and leader and physician founder of this anti-aging revolution and great healthcare specialty, Dr. Ron Klatz, MD, DO was asked about the benefits to those communities around the world who are adopting the anti-aging lifestyle.
He stated, that those communities all over the world are enjoying a life expectancy of 91.5 years average versus the standard 68-year life expectancy for those only receiving standard care. This is a 23.5-year difference….hence the coined term, “the anti-aging dividend.”” -David A. Kekich, Maximum Life Foundation, Longevity Press Release, Dec 31, 2015

YOUR COMMENT Login or Register to post a comment.

Next entry: #1: Seven Emerging Technologies That Will Change the World Forever

Previous entry: Survival of Extremely Premature Infants Opens New Ethical Decisions